دورية أكاديمية
Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
| العنوان: | Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA). |
|---|---|
| المؤلفون: | Coffin CS; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada., Haylock-Jacobs S; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada., Doucette K; Department of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada., Ramji A; Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada., Ko HH; Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada., Wong DK; Department of Medicine, University of Toronto, Toronto, ON M5G 2CV, Canada., Elkhashab M; Toronto Liver Centre, Toronto, ON M6H 3M1, Canada., Bailey R; Bailey Health Clinic, Edmonton, AB T5H 4B9, Canada., Uhanova J; Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada., Minuk G; Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada., Tsoi K; Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada., Wong A; Department of Medicine, University of Saskatchewan, Regina, SK S7N 5A2, Canada., Ma MM; Department of Medicine, University of Alberta, Edmonton, AB T6G 2R3, Canada., Tam E; Pacific Gastroenterology Associates, Vancouver, BC V6Z 2K5, Canada., Brahmania M; Multi Organ Transplant Unit, Department of Medicine, Division of Gastroenterology, Western University, London, ON N6A 3K7, Canada., Nudo C; Cité-de-la-Santé de Laval, Laval, QC H7M 3L9, Canada., Zhu J; Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada., Lowe CF; Division of Medical Microbiology, Providence Health Care, Vancouver, BC V6Z 1Y6, Canada., Osiowy C; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada., Lethebe BC; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada., Congly SE; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada., Chan EKH; Janssen Global Services LC, Raritan, NJ 08869, USA., Villasis-Keever A; Janssen Global Services LC, Raritan, NJ 08869, USA., Sbarigia U; Janssen Pharmaceuticals NV, 2340 Beerse, Belgium., Cooper CL; Department of Medicine, Division of infectious Diseases, University of Ottawa, Ottawa, ON K1N 6N5, Canada., Fung S; Department of Medicine, University of Toronto, Toronto, ON M5G 2CV, Canada. |
| المصدر: | Viruses [Viruses] 2022 Nov 29; Vol. 14 (12). Date of Electronic Publication: 2022 Nov 29. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مواضيع طبية MeSH: | Hepatitis B, Chronic* , Carcinoma, Hepatocellular*/drug therapy , Liver Neoplasms*/drug therapy, Adult ; Humans ; Female ; Middle Aged ; Male ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; Retrospective Studies ; Hepatitis B e Antigens ; Antigens, Surface ; Cohort Studies ; Cross-Sectional Studies ; Canada/epidemiology ; Antiviral Agents/therapeutic use ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/complications ; DNA, Viral |
| مستخلص: | Background: Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes for individuals with chronic hepatitis B (CHB); however, the effects of varying HBsAg levels on clinical outcomes in diverse cohorts are understudied. Methods: In this cross-sectional, multicentre, retrospective study, the data on adult subjects enrolled in the Canadian HBV Network with CHB seen from 1 January 2012 to 30 January 2021 with the treatment and virologic data within 1 year of HBsAg testing were analyzed. Patients were tested for HBsAg using qualitative (for HBsAg-negative samples) and/or commercial quantitative assays. Fibrosis or hepatic necroinflammation was determined by the liver stiffness measurement (LSM). The baseline data were summarized using descriptive statistics and compared by using univariable/multivariable analyses. Results: This study included 844 CHB patients, with a median age of 49.6 years (IQR 40.1-60.5), and 37% were female. In total, 751 patients (78.6%) had known ethnicity data, and 76.7% self-reported as Asian, 11.4% as Black, 6.8% as White, and 4.8% as other. Among the 844 patients, 237 (28.0%) were HBsAg (-) ( Conclusion: In this retrospective, ethnically diverse cohort study, CHB patients who received antiviral therapy and/or had HBsAg loss were less likely to develop cirrhosis and HCC, confirming the results of the studies in less diverse cohorts. No association was found between the qHBsAg level and fibrosis determined with LSM. Individuals who achieved HBsAg loss had low-level qHBsAg within 1 year of seroclearance. |
| References: | CMAJ Open. 2019 Oct 22;7(4):E610-E617. (PMID: 31641059) Liver Int. 2015 Jan;35(1):130-9. (PMID: 25145784) J Hepatol. 2017 Feb;66(2):398-411. (PMID: 27575311) Gut. 2014 Oct;63(10):1648-57. (PMID: 24225939) Hepatology. 2018 Aug;68(2):425-434. (PMID: 29108132) Hepatology. 2016 Aug;64(2):381-9. (PMID: 27079545) CMAJ. 2010 Nov 23;182(17):1864-73. (PMID: 20940232) Liver Int. 2017 Nov;37(11):1642-1650. (PMID: 28345181) Gastroenterology. 2019 Feb;156(3):548-551. (PMID: 30641057) Aliment Pharmacol Ther. 2021 Jan;53(2):321-331. (PMID: 33222272) Clin Liver Dis. 2019 Aug;23(3):401-416. (PMID: 31266616) Ann Intern Med. 1993 Feb 1;118(3):191-4. (PMID: 8417636) JAMA Oncol. 2017 Dec 1;3(12):1683-1691. (PMID: 28983565) Gastroenterology. 2011 Aug;141(2):517-25, 525.e1-2. (PMID: 21672542) Liver Int. 2015 Jan;35(1):140-7. (PMID: 24393326) Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):631-641. (PMID: 31477873) Ann Hepatol. 2018 Mar - Apr;17(2):232-241. (PMID: 31097238) J Hepatol. 2013 May;58(5):853-60. (PMID: 23246508) Gut. 2019 Dec;68(12):2206-2213. (PMID: 31462554) J Clin Virol. 2013 Aug;57(4):323-30. (PMID: 23731848) Liver Int. 2013 Oct;33(9):1363-9. (PMID: 23763288) Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. (PMID: 29599078) Gastroenterology. 2019 Feb;156(3):635-646.e9. (PMID: 30342034) J Hepatol. 2020 Oct;73(4):800-806. (PMID: 32504663) Gastroenterol Hepatol. 2020 Nov;43(9):526-536. (PMID: 32921478) Aliment Pharmacol Ther. 2014 Dec;40(11-12):1262-9. (PMID: 25312649) Can Liver J. 2018 Dec 25;1(4):156-217. (PMID: 35992619) Viruses. 2019 Jul 26;11(8):. (PMID: 31357522) J Infect Dis. 2021 Dec 1;224(11):1890-1899. (PMID: 33999179) Hepatology. 2016 Jan;63(1):284-306. (PMID: 26566246) J Hepatol. 2003 Mar;38(3):257-65. (PMID: 12586290) Lancet Gastroenterol Hepatol. 2019 Mar;4(3):227-238. (PMID: 30679109) Aliment Pharmacol Ther. 2016 Aug;44(4):390-9. (PMID: 27363288) Hepatology. 2022 Mar;75(3):709-723. (PMID: 34743343) |
| فهرسة مساهمة: | Keywords: Canada; HBsAg loss; functional cure; multiethnic; quantitative HBsAg |
| المشرفين على المادة: | 0 (Hepatitis B Surface Antigens) 0 (Hepatitis B e Antigens) 0 (Antigens, Surface) 0 (Antiviral Agents) 0 (DNA, Viral) |
| تواريخ الأحداث: | Date Created: 20221223 Date Completed: 20221226 Latest Revision: 20230131 |
| رمز التحديث: | 20230131 |
| مُعرف محوري في PubMed: | PMC9781785 |
| DOI: | 10.3390/v14122668 |
| PMID: | 36560672 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1999-4915 |
|---|---|
| DOI: | 10.3390/v14122668 |